Elanco Receives EC’s Approval for its Pending Acquisition of Bayer Animal Health

 Elanco Receives EC’s Approval for its Pending Acquisition of Bayer Animal Health

Elanco Receives EC’s Approval for its Pending Acquisition of Bayer Animal Health

Shots:

  • The EC has granted approval of Elanco’s pending acquisition of Bayer’s animal health business. The company continues to progress toward a mid-year closing, anticipated Aug 03, 2020
  • The EC’s approval follows the divestiture of global rights for Osurnia to treat otitis externa in dogs, WW rights of Vecoxa to prevent & treat coccidiosis in calves and lambs being sold to Merck Animal Health and the European Economic Area and UK rights to the Drontal and Profende product families with related pipeline assets being sold to Vetoquinol SA
  • In addition to EC approval, Elanco has received antitrust clearance for the transaction in China, Colombia, South Africa, Turkey, Ukraine, Vietnam, and provisional clearance in Brazil

Click here, ­to­ read full press release/ article | Ref: Elanco | Image: Livemint

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post